Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study

BACKGROUND: Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associated with reduced quality of life. Masitinib inhibits KIT and LYN kinases that are involved in indolent systemic mastocytosis pathogenesis. We aimed to assess safe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lancet
Päätekijät: Lortholary, Olivier, Chandesris, Marie Olivia, Livideanu, Cristina Bulai, Paul, Carle, Guillet, Gérard, Jassem, Ewa, Niedoszytko, Marek, Barete, Stéphane, Verstovsek, Srdan, Grattan, Clive, Damaj, Gandhi, Canioni, Danielle, Fraitag, Sylvie, Lhermitte, Ludovic, Lavialle, Sophie Georgin, Frenzel, Laurent, Afrin, Lawrence B, Hanssens, Katia, Agopian, Julie, Gaillard, Raphael, Kinet, Jean-Pierre, Auclair, Christian, Mansfield, Colin, Moussy, Alain, Dubreuil, Patrice, Hermine, Olivier
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5985971/
https://ncbi.nlm.nih.gov/pubmed/28069279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(16)31403-9
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia